SCHEMBL6890748

SCHEMBL6890748

CCOC(=O)CC(=O)C1CCSCC1

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GAA P10253 4/20 0.48
MGAM O43451 1/20 0.48
SI P14410 1/20 0.48
MGAM2 Q2M2H8 1/20 0.48
EPHX2 P34913 2/20 0.37
ALDH1A1 P00352 3/20 0.36
TRPA1 O75762 1/20 0.36
SMYD3 Q9H7B4 1/20 0.35
KMT2A Q03164 2/20 0.34
ALOX15 P16050 2/20 0.34
MEN1 O00255 1/20 0.34
LMNA P02545 1/20 0.34
HPGD P15428 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
HSD17B10 Q99714 1/20 0.34
JAK1 P23458 1/20 0.33
TP53 P04637 1/20 0.33
MAPT P10636 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1014646 0.87 GAA (0.58) GAAMGAMSIMGAM2EPHX2
SCHEMBL2005270 0.83 GAA (0.54) GAAMGAMSIMGAM2EPHX2
SCHEMBL1617817 0.83 GAA (0.54) GAAMGAMSIMGAM2ALDH1A1
SCHEMBL434421 0.81 MGAM (0.52) GAAMGAMSIMGAM2ALDH1A1
SCHEMBL13848940 0.79 GAA (0.48) GAAMGAMSIMGAM2ALDH1A1
SCHEMBL771683 0.79 GAA (0.48) GAAMGAMSIMGAM2ALDH1A1
SCHEMBL10236626 0.79 GAA (0.51) GAAMGAMSIMGAM2ALDH1A1
SCHEMBL4997648 0.79 GAA (0.48) GAAMGAMSIMGAM2EPHX2
SCHEMBL2680543 0.79 GAA (0.51) GAAMGAMSIMGAM2ALDH1A1
SCHEMBL6615786 0.78 MGAM (0.41) GAAMGAMSIMGAM2EPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4741392-A1 1H-PYRAZOLO[4,3-C]PYRIDINE COMPOUND, AND COMPOSITION THEREOF AND USE THEREOF Shenzhen TargetRx Co., Ltd. (CN) 2026-05-13 EP disclosed
WO-2025007863-A1 1H-PYRAZOLO[4,3-C]PYRIDINE COMPOUND, AND COMPOSITION THEREOF AND USE THEREOF 深圳市塔吉瑞生物医药有限公司 2025-01-09 WO disclosed
EP-2448942-B1 FUSED TRICYCLIC COMPOUNDS AS mTOR INHIBITORS MERCK SHARP & DOHME (US) 2014-09-24 EP disclosed
US-20120178744-A1 FUSED TRICYCLIC COMPOUNDS AS NOVEL mTOR INHIBITORS MERCK SHARP & DOHME LLC 2012-07-12 US disclosed
US-20120178744-A1 FUSED TRICYCLIC COMPOUNDS AS NOVEL mTOR INHIBITORS MERCK SHARP & DOHME LLC 2012-07-12 US disclosed
WO-2011002887-A1 FUSED TRICYCLIC COMPOUNDS AS NOVEL mTOR INHIBITORS SCHERING CORPORATION (US) 2011-01-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120178744-A1 FUSED TRICYCLIC COMPOUNDS AS NOVEL mTOR INHIBITORS MTOR, RICTOR, RPTOR GAA 2432/4885MGAM 4072/4885SI 3375/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.